Search

everythinglearnresearchcommunity

for

Search:↓

Nail changes in alopecia areata are common and may indicate severity and genetic risk.

Nail problems are common in people with alopecia areata, often leading to cosmetic and functional issues, but more research is needed for treatment guidelines.

New tools help assess eyebrow, eyelash, and nail changes in Alopecia Areata, improving understanding of patient experiences.

Most people with alopecia areata have nail changes, which are common but don't greatly affect their quality of life.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Younger patients with severe alopecia areata often have nail problems.

Nail issues are common in kids with alopecia areata and should be checked for better diagnosis.

Nail changes are common in alopecia areata and can indicate its severity.

Baricitinib may effectively treat nail changes in alopecia areata.

RDW can be a useful marker for inflammation in alopecia areata patients.

Patients with alopecia areata and eosinophilia have more nail issues and severe hair loss.

"20-nail dystrophy" can have multiple causes.

A child with rough nails also had hair loss and allergies.

Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.

A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.

Talquetamab may cause hair loss and skin issues.

Alopecia areata is an unpredictable autoimmune hair loss condition, treated based on severity, with half of patients regrowing hair within a year without treatment.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

Alopecia areata mainly affects young people, often showing as patchy hair loss on the scalp.

Scalp alopecia areata mostly affects young adult males, often starts suddenly, and usually presents as single, patchy lesions.

Alopecia areata severity is influenced by factors like long disease duration, relapses, treatment response, and mental health, leading to the creation of a new severity measurement tool.

The study concluded that short vellus hair and yellow dots were the most common signs of alopecia areata, indicating disease activity and remission.

Alopecia areata is more common in males, mostly affects the scalp, and often appears as patchy hair loss.

Younger children with alopecia areata often experience more severe hair loss and longer illness, with allergies and nutrient deficiencies playing a role.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

JAK inhibitors show promise in effectively treating hair loss from alopecia areata.

Alopecia areata patients, especially women with nail issues or atopic diseases, are at higher risk for other autoimmune diseases.

Systemic steroids effectively treated severe nail issues in a card illusionist with alopecia areata.

Intramuscular corticosteroids are effective and safe for severe alopecia areata, with most patients regrowing hair, but nearly half may relapse.